New study tests nausea drug for breast cancer patients on powerful therapy
NCT ID NCT07132749
First seen Jan 11, 2026 · Last updated Apr 29, 2026 · Updated 10 times
Summary
This study looks at whether the anti-nausea drug NEPA can help control vomiting and nausea in people with advanced HER2-positive or HER2-low breast cancer who are being treated with T-DXd. About 100 adults will take part, and researchers will track how well NEPA works over several days after each chemo session. The goal is to improve comfort during treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH HER2-POSITIVE ADVANCED BREAST CANCER TREATED WITH T-DXD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Samsung Medical Center
Seoul, Gangnam-gu, 06355, South Korea
Conditions
Explore the condition pages connected to this study.